comparison qis5 and parallel run -...
TRANSCRIPT
© 2012 Towers Watson. All rights reserv ed.
Comparison QIS5 and Parallel Run
Overview of similarities and differences
Towers Watson Netherlands - Risk Consulting & Software
May 2012
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
2
Contents
Introduction
Main conclusions
Technical Provisions
Solvency Capital Requirement (SCR)
Market Risk
Life Risk
Non-Life Risk
Health Risk
Operational / Intangible Asset / Default Risk
Other
Limitations
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
3
Introduction
The objective is to give a brief overview of the main similarities and differences
between QIS5 and the Parallel Run.
Sources:
QIS 5: QIS5-technical_specifications_20100706.pdf
Parallel Run: Solvency II_Parallel Run over 2011_Handleiding en technische
specificaties_tcm50-225969.pdf
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
Main conclusions
4
Change in basis risk free interest rates. Last liquid point is only 20 years. After
20 years risk free rates converge in next 40 years to Ultimate Forward Rate of
4.2%.
Introduction of countercyclical premium based on 75% of QIS5 proxy method
without bucketing. Slight run-off countercyclical premium after 20 years, but
remains substantial for longer tenors.
Whole impact Countercyclical premium part of SCR Market risk module with
correlation 0 with other market risks.
Symmetric adjustment for the equity shock decreased from 9% to 5%.
Lapse stress changed for Life, non-Life and Health.
Some Non-Life and Health parameters for premium and reserve risk have
been changed.
Additional reporting disclosures such as net present values of different
incoming and outgoing cash flows and surrender values.
The range of application of scenarios for Catastrophe risk has been changed.
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
Technical Provisions
5
QIS 5 Parallel Run
Valuation
Risk-free rate Liabilities should be discounted with the risk-free rate plus an illiquidity premium.
As risk-free rate should be used the Swap-
curve - 10 basis points for the first 30 years. Between 30 and 60 years forward converges to
the ultimate forward rate of 4.2%.
See page 50 and annex E
The risk-free interest rate is based on the swap curve adjusted for 10bps for credit risk.
The last liquid point is assumed to be 20 years.
After 20 years the rates converge in 40 years according the Smith-Wilson model to the Ultimate
Forward Rate (UFR) of 4.2%.
See page 66
Illiquidity premium /
Countercyclical premium
50%, 75% or 100% illiquidity premium, depending on type of liability.
See page 50
Countercyclical premium of 75% of the proxy method from QIS5 for first 20 years. No bucketing.
After 20 years countercyclical premium decreases slowly, but remains significant.
Matching premium out of scope.
Insurers are allowed to make an extra valuation with a 100% countercyclical premium.
See page 67
Risk Margin Risk Margin Part of TP in order to ensure that the value is equivalent to the amount that (re)insurance undertakings would be expected to require in
order to take over and meet the (re)insurance obligations.
See page 54-55
This is calculated as the present value of 6% (CoC) of the future SCR’s (discounted with the
appropriate rate).
See page 58
No changes in calculation. The discount rates should be basis risk free rate without the countercyclical premium.
See page 26
(1) We note the latest proposal of the ECON commission of the European Parliament includes a risk -f ree rate based on the Swap-curv e – 10 basis points until 20 y ears. Then the curv e
will be extrapolated to the ultimate f orward rate of 4,2% in 10 y ears.
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
6
Solvency Capital Requirement (SCR)
*
* Illiquidity under QIS5, Countercyclical premium in Parallel Run
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
SCR - Market Risk
7
QIS 5 Parallel Run
Interest Shift of whole curve up and down.
See page 110-111
Shift of whole curve up and down. Changed shocks after 20 years. Shock for each term is minimum 100 basis points for up and down shocks.
See page 68
Equity Stress: on two different types of equity, stresses take account of (9%) symmetric adjustment.
See page 112-115
Stress: on two different types of equity, stresses take account of (5%) symmetric adjustment.
See page 15
Duration based equity approach is not allowed.
See page 17
Property Stress: instant 25% decrease in real estate investments.
See page 116-117
No changes.
See page 30
Currency Stress up: instant 25% rise of currency.
Stress down: instant 25% fall of currency.
See page 117-119
No changes.
See page 52
Spread The spread is split up in:
Bonds
Structured credit products
Credit derivatives
Required capital is computed as the decrease in spread, based on
credit rating. See page 119-127
No spread risk on European Economic Area (EEA) government bonds See page 123
Spreads changed with different segmentation of durations which leads to smoother transfer of capital requirements from short to long durations of corporate bonds.
See appendix D page 69-74
Residential mortgages are part of counterparty default risk.
See page 17
For credit derivatives used for risk mitigation no capital requirement when the underlying assets are owned and no other material exposure is present.
See page 73-74
Concentration Maximum exposure per counterparty depends on credit rating. See page 127-132
For unrated (re)insurers no reference can be made to SII ratio, capital requirement will be based on poorest credit rating.
See page 88-89
Illiquidity /
Countercyclical premium
Stress: instant 65% fall in value of illiquidity premium with a correlation of -0.5 with spread risk.
See page 109, 132-133
Stress: instant 100% decrease of the countercyclical premium with correlation 0 with other market risks. Whole impact countercyclical premium part of SCR Market Risk module.
See page 13
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
SCR – Life Risk
8
QIS 5 Parallel Run
Mortality Stress: 15% increase in mortality rates.
See page 149-150
No changes.
See page 30
Longevity Stress: 20% decrease in mortality rates.
See page 151-152
No changes.
See page 30
Disability Stress: 35% increase in next year disability rates, thereafter 25% permanent increase and a permanent 20% decrease in recovery rates.
See page 152-155
No changes.
See page 54
Lapse The maximum of an: up, down and mass-lapse stress.
See page 155-159
Mass-lapse stress up from 30% to 40% for Retail (Individual) business.
See page 18
DNB explicitly mentioned the extended lapse definition including paid up.
See page 17
Expense Stress: 10% increase in future expenses and 1% per annum increase of the expense inflation rate.
See page 159-160
No changes.
See page 30
Revision Stress: 3% increase in the annual amount payable for annuities exposed to revision risk. See page 160-161
No changes. No details provided in specifications.
Catastrophe Stress: 15 basispoints increase in mortality rates over next year.
See page 161-163
No changes. No details provided in specifications.
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
SCR – Non-Life Risk
9
QIS 5 Parallel Run
Premium and Reserve Function of st.dev. times Volume:
Approx 3 * st.dev. * Vol
St.Dev. and Volume are split in 12 LoB’s
St.Dev. is given per LoB and Volume is computed from written and earned premium per LoB (premium risk) and claims outstanding (reserve risk).
See page 196-203
3 * st.dev. * Vol
Lob’s are replaced by segments.
Calculation of premium volume is adapted. Parameters now only include earned premiums (no written premiums). Premium
volume now also includes the value of expected premiums for policies with start date after calculation date.
Parameters for premium and reserve risk are altered. Only one estimation method for entity specific parameters is allowed. ρ is
set to 3.
See pages 20, 75, 90
Lapse Same as in Life (without non-retail).
See page 203-205
Changed from Life. The discontinuance of 40% of both the insurance and reinsurance policies for which this discontinuance results in a higher best estimate. For outgoing
reinsurance contracts related to future contracts: a decrease of 40% of the expected number of future policies.
See pages 18, 55
Catastrophe Compute via standardized scenarios and factor based methods and aggregate using zero correlation.
See page 206-243
Changes in cat risk for motor liability and credit and suretyship. The scenario for a man-made motor liability catastrophe depends on the number of insured vehicles grouped by the
maximum claim size. Solvency capital for the credit and suretyship catastrophe risk consists of a default and a
recession component. For each component an altered scenario is prescribed.
See pages 21, 79-80
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
SCR – Health Risk
10
QIS 5 Parallel Run
SLT
(Similar to Life
Techniques)
Mortality Same as in Life.
See page 168-169
No changes.
See pages 30, 56
Longevity Same as in Life.
See page 169
No changes.
See pages 30, 56
Disability/
morbidity
Sum of Medical and Income
Medical expense insurance, max of claim shock up and claim shock down
Income protection insurance, same as in Life.
See page 169-173
No changes.
See page 56
Lapse Same as in Life, except with 20% instead of 50% for up and down stress.
See page 174
For increased and decreased discontinuance: same as in Life. For mass lapse, same as in Non-Life (or Life without non-retail).
See page 19
Expense Same as in Life
See page 173
No changes.
See pages 30, 57
Revision Same as in Life, but with 4% stress instead of 3% (with a possibility of USPs).
See page 173-174
No changes.
See page 57
Non-SLT Premium &
Reserve
Same as in Non-Life, but with 4 LoB’s .
See page 174-180
Same changes as in Non-Life. The reduction of the parameters due to HRES have changed.
See pages 20, 75, 90
Lapse Same as in Life (without non-retail).
See page 180-183
Same as in Non-Life.
See pages 19, 57
Catastrophe Split in 3 uncorrelated events:
Arena (Mass), Concentration and Pandemic.
For medical expenses Arena and Pandemic do not apply. See page 186-195
The range of application of the scenarios has changed.
Where in QIS5 only concentration risk was applicable for medical expenses, in the Parallel Run the concentration risk is the only
risk that is not applicable for medical expenses.
Furthermore, Arena is replaced by mass accident risk. Pandemic risk is adapted to include medical costs. Risk
Equalisation Fund should be considered when determining solvency requirement for pandemic for basic health insurance. See pages 79-83
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
SCR – Operational / Intangible Asset / Default Risk
11
QIS 5 Parallel Run
Operational SCR = min(0.3⋅BSCR;Op) + 0.25⋅Exp.
Where Op is based on premiums and provisions.
See page 102-104
Slight change in factor from 1.1 to 1.2 in formula of Oppremiums.
See page 58
Intangible Asset 80% of Value Intangible Assets.
See page 105
No changes.
See page 51
Counterparty default Split in type 1 and type 2 exposure, with 75% correlation. Type 1 are exposures which may not be diversified and where the counterparty is likely
to be rated.
Type 2 are exposures which are usually diversified
and where the counterparty is likely to be unrated.
SCR is based on Loss-Given-Default per counterparty.
See page 134-146
Split in type 1 and type 2 exposure. Residential mortgages are part of counterparty default risk under type 2.
See page 17
Use of simplified methods from QIS5 is allowed.
See page 87
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
Other
12
QIS 5 Parallel Run
Contract boundaries Annex D of the QIS5 specifications sets out examples of contract boundaries
See page 27-28 and annex D
DNB made further clarifications. The implications of the ‘en-bloc clausules’ are still left to the judgment of the insurer.
See page 61-65
Employee benefits IFRS treatment recommended. Valuation based on Solvency II principles are allowed with sufficient documentation.
See page 19
IFRS, BW valuation and other valuation techniques allowed which lead to market value.
See page 13
Insurer may choose to stress, but treatment should be disclosed. Stress is not mandatory.
See page 14
Loss absorbency of technical
provisions and deferred tax
Two approaches were tested:
•Equivalent scenario
•Modular approach
See 97-101
Only modular approach should be used.
See page 14
Net approach for deferred tax assets is allowed when covered
by future profits in foreseeable future. Starting point is the shocked position.
See page 84-85
Undertaking-specific
parameters
Undertakings are encouraged to calculate undertaking-specific parameters. USPs can be applied for premium and reserve risk and for
revision risk
See page 244-260
Only one method based on lognormal distribution is allowed for standard deviation of premium and reserve risk.
See page 21
Additional Disclosures No additional disclosure needed of net present values of cash flows or surrender values.
Additional disclosure needed of net present value of incoming and outgoing cash flows and surrender values.
See page 40 and 47
Expected loss separately disclosed in reporting tool.
See page 29
MCR Minimum Capital Requirement
See page 287-294
No changes.
See page 31
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
Limitations
The information in this publication has been prepared for general purposes only
and does not purport to be and is not a substitute for specific professional advice.
While the matters identified are believed to be generally correct, before any
specific action is taken, specific advice on the circumstances in question should
be obtained.
13
towerswatson.com
© 2012 Towers Watson. All rights reserved. Proprietary and Confidential. For Towers Watson and Towers Watson client use only.
14
Comparison QIS5 and Parallel Run
Towers Watson Netherlands – Risk Consulting & Software For more details and questions please contact:
Gerard Pater, Dennis Bank or Suzanne Overberg